These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 17122530

  • 1. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
    Ollendorf DA, Lidsky L.
    Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
    [Abstract] [Full Text] [Related]

  • 2. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
    Carter CT, Waters HC, Smith DB.
    Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
    [Abstract] [Full Text] [Related]

  • 3. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
    Kane SV, Chao J, Mulani PM.
    Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
    [Abstract] [Full Text] [Related]

  • 4. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
    Lindsay J, Punekar YS, Morris J, Chung-Faye G.
    Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
    [Abstract] [Full Text] [Related]

  • 5. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
    Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF.
    Value Health; 2008 Jul; 11(5):820-9. PubMed ID: 18489509
    [Abstract] [Full Text] [Related]

  • 6. Infliximab use in luminal Crohn's disease.
    Richter JA, Bickston SJ.
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [Abstract] [Full Text] [Related]

  • 7. Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence.
    Feagan BG, Kozma CM, Slaton TL, Olson WH, Wan GJ.
    J Med Econ; 2014 Dec; 17(12):872-80. PubMed ID: 25162777
    [Abstract] [Full Text] [Related]

  • 8. Resource use in patients with Crohn's disease treated with infliximab.
    Saro C, da la Coba C, Casado MA, Morales JM, Otero B.
    Aliment Pharmacol Ther; 2007 Nov 15; 26(10):1313-23. PubMed ID: 17850419
    [Abstract] [Full Text] [Related]

  • 9. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA, Villela R, Silverberg MS, Greenberg GR.
    Clin Gastroenterol Hepatol; 2006 Oct 15; 4(10):1248-54. PubMed ID: 16931170
    [Abstract] [Full Text] [Related]

  • 10. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
    Kuin S, Stolte SB, van den Brink GR, Ponsioen CY, Fockens P, D'Haens GR, Löwenberg M.
    Eur J Gastroenterol Hepatol; 2016 Feb 15; 28(2):222-5. PubMed ID: 26566062
    [Abstract] [Full Text] [Related]

  • 11. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States.
    Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A.
    Am J Gastroenterol; 2016 Jan 15; 111(1):15-23. PubMed ID: 26195179
    [Abstract] [Full Text] [Related]

  • 12. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.
    Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.
    J Med Econ; 2012 Jan 15; 15(2):264-75. PubMed ID: 22115327
    [Abstract] [Full Text] [Related]

  • 13. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
    Jackson J, Fernandes AW, Nelson W.
    Clin Ther; 2006 Sep 15; 28(9):1462-71. PubMed ID: 17062318
    [Abstract] [Full Text] [Related]

  • 14. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ.
    Eur J Gastroenterol Hepatol; 2009 Jan 15; 21(1):71-5. PubMed ID: 19060632
    [Abstract] [Full Text] [Related]

  • 15. The cost of hospitalization in Crohn's disease.
    Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL.
    Am J Gastroenterol; 2000 Feb 15; 95(2):524-30. PubMed ID: 10685762
    [Abstract] [Full Text] [Related]

  • 16. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center.
    Stephens MC, Shepanski MA, Mamula P, Markowitz JE, Brown KA, Baldassano RN.
    Am J Gastroenterol; 2003 Jan 15; 98(1):104-11. PubMed ID: 12526944
    [Abstract] [Full Text] [Related]

  • 17. Dose intensification with infliximab in patients with rheumatoid arthritis.
    Berger A, Edelsberg J, Li TT, Maclean JR, Oster G.
    Ann Pharmacother; 2005 Dec 15; 39(12):2021-5. PubMed ID: 16288073
    [Abstract] [Full Text] [Related]

  • 18. Assessing incidence and economic burden of genital warts with data from a US commercially insured population.
    Hoy T, Singhal PK, Willey VJ, Insinga RP.
    Curr Med Res Opin; 2009 Oct 15; 25(10):2343-51. PubMed ID: 19650749
    [Abstract] [Full Text] [Related]

  • 19. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.
    J Drugs Dermatol; 2008 Jan 15; 7(1):41-9. PubMed ID: 18246697
    [Abstract] [Full Text] [Related]

  • 20. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study.
    Gilbert TD, Smith D, Ollendorf DA.
    BMC Musculoskelet Disord; 2004 Oct 14; 5(1):36. PubMed ID: 15485582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.